{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prevenar+13&page=2", "query": { "intervention": "Prevenar 13", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prevenar+13&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T15:23:16.114Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01000974", "title": "Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Haemophilus Influenzae Type b" ], "interventions": [ { "name": "GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)", "type": "BIOLOGICAL" }, { "name": "ActHIB™", "type": "BIOLOGICAL" }, { "name": "Pentacel™", "type": "BIOLOGICAL" }, { "name": "Pediarix™", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "Rotarix™", "type": "BIOLOGICAL" }, { "name": "Engerix™-B", "type": "BIOLOGICAL" }, { "name": "Infanrix™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "sex": "ALL", "summary": "6 Weeks to 12 Weeks" }, "enrollment_count": 4003, "start_date": "2010-06-18", "completion_date": "2013-07-17", "has_results": true, "last_update_posted_date": "2018-07-12", "last_synced_at": "2026-09-25T15:23:16.114Z", "location_count": 63, "location_summary": "Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Benton", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01000974" }, { "nct_id": "NCT00980655", "title": "Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Vaccines, Pneumococcal Conjugate Vaccine" ], "interventions": [ { "name": "13vPnC", "type": "BIOLOGICAL" }, { "name": "23vPS", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 251, "start_date": "2010-01-18", "completion_date": "2013-05-16", "has_results": true, "last_update_posted_date": "2018-12-20", "last_synced_at": "2026-09-25T15:23:16.114Z", "location_count": 9, "location_summary": "Lexington, Kentucky • New Hyde Park, New York • New York, New York + 2 more", "locations": [ { "city": "Lexington", "state": "Kentucky" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00980655" }, { "nct_id": "NCT03039491", "title": "Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "HIV Lipodystrophy", "Aging" ], "interventions": [ { "name": "Pneumococcal polysaccharide vaccine 23 valent", "type": "BIOLOGICAL" }, { "name": "13 valent conjugated pneumococcal vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 160, "start_date": "2015-09-01", "completion_date": "2020-03-30", "has_results": false, "last_update_posted_date": "2020-06-16", "last_synced_at": "2026-09-25T15:23:16.114Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03039491" }, { "nct_id": "NCT04080531", "title": "Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Plasma Cell Neoplasm" ], "interventions": [ { "name": "Pneumococcal 13-valent Conjugate Vaccine", "type": "BIOLOGICAL" }, { "name": "Trivalent Influenza Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2019-10-18", "completion_date": "2022-12-15", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-09-25T15:23:16.114Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04080531" }, { "nct_id": "NCT00824850", "title": "Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pneumococcal Conjugate Vaccine" ], "interventions": [ { "name": "13-valent Pneumococcal Conjugate Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "8 Years to 16 Years" }, "enrollment_count": 75, "start_date": "2010-01", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2011-11-11", "last_synced_at": "2026-09-25T15:23:16.114Z", "location_count": 2, "location_summary": "Hayward, California • San Jose, California", "locations": [ { "city": "Hayward", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00824850" }, { "nct_id": "NCT03207750", "title": "This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rotavirus Infection", "Rotavirus Vaccines" ], "interventions": [ { "name": "Rotarix", "type": "BIOLOGICAL" }, { "name": "Pediarix", "type": "BIOLOGICAL" }, { "name": "Hiberix", "type": "BIOLOGICAL" }, { "name": "Prevenar 13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "sex": "ALL", "summary": "6 Weeks to 12 Weeks" }, "enrollment_count": 1280, "start_date": "2017-09-14", "completion_date": "2019-03-01", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-09-25T15:23:16.114Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Daly City", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03207750" }, { "nct_id": "NCT03950856", "title": "Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections", "Pneumonia, Pneumococcal" ], "interventions": [ { "name": "V114", "type": "DRUG" }, { "name": "Prevnar 13™", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 2340, "start_date": "2019-06-12", "completion_date": "2020-04-03", "has_results": true, "last_update_posted_date": "2021-04-12", "last_synced_at": "2026-09-25T15:23:16.114Z", "location_count": 30, "location_summary": "Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Paramount", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03950856" }, { "nct_id": "NCT03819049", "title": "A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Extraintestinal Pathogenic Escherichia Coli Prevention" ], "interventions": [ { "name": "ExPEC10V", "type": "BIOLOGICAL" }, { "name": "ExPEC4V", "type": "BIOLOGICAL" }, { "name": "Prevnar 13", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 836, "start_date": "2019-06-06", "completion_date": "2024-12-18", "has_results": true, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-25T15:23:16.114Z", "location_count": 12, "location_summary": "Huntsville, Alabama • Melbourne, Florida • Miami, Florida + 9 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03819049" }, { "nct_id": "NCT03056924", "title": "Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Inflammatory Bowel Diseases" ], "interventions": [ { "name": "Pneumococcal Pneumonia vaccine", "type": "BIOLOGICAL" }, { "name": "Influenza vaccine", "type": "BIOLOGICAL" }, { "name": "Hepatitis B vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 173, "start_date": "2017-07-05", "completion_date": "2019-01-15", "has_results": false, "last_update_posted_date": "2019-12-30", "last_synced_at": "2026-09-25T15:23:16.114Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03056924" }, { "nct_id": "NCT03692871", "title": "A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "90 Days", "sex": "ALL", "summary": "42 Days to 90 Days" }, "enrollment_count": 2409, "start_date": "2018-12-14", "completion_date": "2021-03-26", "has_results": true, "last_update_posted_date": "2023-07-28", "last_synced_at": "2026-09-25T15:23:16.114Z", "location_count": 22, "location_summary": "Downey, California • Huntington Beach, California • San Diego, California + 18 more", "locations": [ { "city": "Downey", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Santa Clara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03692871" } ] }